TrialThe Lancet. Infectious diseases2011

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

PENPACT-1 (PENTA 9/PACTG 390) Study Team et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.